v3.26.3
Segment, Geographic and Other Revenue Information - Revenues by Products (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 27, 2026
Sep. 28, 2025
Sep. 27, 2026
Sep. 28, 2025
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: $ 16,583 $ 16,654 $ 46,067 $ 45,022
Alliance revenues 2,851 2,298 7,888 6,684
Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [1] 16,283 16,310 45,105 44,056
Biopharma [Member] | U.S. Commercial Division [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 9,677 9,854 25,319 25,437
Biopharma [Member] | International Commercial Division [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 5,433 5,381 16,211 15,408
Biopharma [Member] | Global Hospital and Biosimilars Division [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [2] 1,172 1,075 3,576 3,211
Pfizer CentreOne [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [3] 300 344 962 966
Total Alliance revenues [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Alliance revenues 2,851 2,298 7,888 6,684
Royalty [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Royalty revenue 477 436 1,347 1,170
Primary Care [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 6,971 7,642 18,017 18,869
Primary Care [Member] | Eliquis [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [4] 2,523 2,015 7,114 5,941
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 1,564 1,742 4,591 4,786
Primary Care [Member] | Nurtec ODT/Vydura [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 547 412 1,321 1,019
Primary Care [Member] | Comirnaty [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 808 1,151 1,301 2,097
Primary Care [Member] | Abrysvo [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 303 279 691 553
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 449 1,225 656 2,144
Primary Care [Member] | FSME-IMMUN/TicoVac [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 104 100 317 272
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 674 718 2,027 2,058
Oncology [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 4,327 3,938 12,318 11,467
Oncology [Member] | Ibrance [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 1,082 1,057 3,148 3,083
Oncology [Member] | Padcev [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 720 464 1,979 1,432
Oncology [Member] | Xtandi [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [5] 541 578 1,519 1,602
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 387 268 1,046 741
Oncology [Member] | Inlyta [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 232 226 665 688
Oncology [Member] | Braftovi/Mektovi [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [6] 244 202 642 519
Oncology [Member] | Adcetris [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [7] 231 215 617 687
Oncology [Member] | Orgovyx [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [8] 153 112 408 285
Oncology [Member] | Tukysa [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 142 110 402 344
Oncology [Member] | Bosulif [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 71 150 313 450
Oncology [Member] | Elrexfio [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 83 85 252 230
Oncology [Member] | Talzenna [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 59 47 166 133
Oncology [Member] | Tivdak [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 39 37 106 115
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 341 386 1,054 1,157
Specialty Care [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 3,349 3,130 9,641 8,834
Specialty Care [Member] | Vyndaqel family [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 1,773 1,591 5,136 4,692
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 213 313 643 763
Specialty Care [Member] | Zavicefta (Outside the U.S. and Canada) [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 179 158 528 457
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 151 154 431 448
Specialty Care [Member] | Octagam [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 134 113 394 298
Specialty Care [Member] | BeneFIX [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 102 94 297 285
Specialty Care [Member] | Cresemba [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 100 83 294 267
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 94 128 281 329
Specialty Care [Member] | Cibinqo [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 101 79 272 206
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 503 417 1,364 1,091
Hospital and Biosimilars [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [1] 1,635 1,600 5,129 4,886
Hospital and Biosimilars [Member] | Oncology Biosimilars [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [9] 378 315 1,145 932
Hospital and Biosimilars [Member] | Inflectra [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 186 173 539 465
Hospital and Biosimilars [Member] | Sulperazon (Outside the U.S. and Canada) [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 96 154 411 484
Hospital and Biosimilars [Member] | Zithromax [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 47 73 200 286
Hospital and Biosimilars [Member] | All Other Hospital and Biosimilars [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: $ 928 $ 885 $ 2,833 $ 2,719
[1] In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation
[2] See Note 13A above.
[3] PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships. Also includes revenues associated with the wind-down of our former Pfizer Ignite operating segment, which were not material in all periods presented. We reclassified prior period amounts to conform to the current period presentation.
[4]
(b)Reflects alliance revenues and product revenues.
[5] Primarily reflects alliance revenues and royalty revenues.
[6] Erbitux® is a registered trademark of ImClone LLC.
[7] Reflects product revenues and royalty revenues.
[8] Reflects alliance revenues.
[9] Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym.